Proteomics

Dataset Information

0

CDK4/6 inhibitors induce repication stress to cause long-term cell cycle withdrawal


ABSTRACT: CDK4/6 inhibitors arrest the cell cycle in G1-phase. They are licenced to treat breast cancer and are also undergoing clinical trials against a range of other tumour types. To facilitate these efforts, it is important to understand why a temporary cell cycle arrest in G1 causes long-lasting effects on tumour growth. Here we demonstrate that a prolonged G1-arrest following CDK4/6 inhibition downregulates replisome components and impairs origin licencing. This causes a failure in DNA replication after release from that arrest, resulting in a p53-dependent withdrawal from the cell cycle. If p53 is absent, then cells bypass the G2-checkpoint and undergo a catastrophic mitosis resulting in excessive DNA damage. These data therefore link CDK4/6 inhibition to genotoxic stress; a phenotype that is shared by most other broad-spectrum anti-cancer drugs. This provides a rationale to predict responsive tumour types and effective combination therapies, as demonstrated by the fact that chemotherapeutics that cause replication stress also induce sensitivity to CDK4/6 inhibition.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell

SUBMITTER: Tony Ly  

LAB HEAD: Tony Ly

PROVIDER: PXD023435 | Pride | 2021-12-20

REPOSITORIES: Pride

Dataset's files

Source:

Similar Datasets

2023-11-17 | PXD043792 | Pride
2023-11-27 | PXD036519 | Pride
2016-01-07 | E-GEOD-76576 | biostudies-arrayexpress
2016-01-07 | GSE76576 | GEO
2012-04-06 | E-GEOD-35728 | biostudies-arrayexpress
2012-04-07 | GSE35728 | GEO
2008-10-25 | E-GEOD-8866 | biostudies-arrayexpress
2024-09-02 | BIOMD0000000660 | BioModels
2008-08-20 | GSE8866 | GEO
2015-09-26 | GSE65040 | GEO